Graft-versus-host disease screening

Graft-versus-host disease
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Graft-versus-host disease from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
Echocardiograph and Ultrasound
CT
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Graft-versus-host disease screening On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Graft-versus-host disease screening All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Graft-versus-host disease screening
CDC on Graft-versus-host disease screening
Graft-versus-host disease screening in the news
Blogs on Graft-versus-host disease screening
Directions to Hospitals Treating Type page name here
Risk calculators and risk factors for Graft-versus-host disease screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Shyam Patel [2]

Overview

Screening of the general population for GvHD is not recommended.

Screening

Screening of the general population for GvHD is not recommended. This is because GvHD can only occur in persons who undergo stem cell transplant, and only a very small fraction of persons will undergo stem cell transplant. The cost of screening to identify persons at risk would outweigh the benefits.